1,721,386 research outputs found
Treatment of secondary mitral regurgitation in patients with heart failure: when left ventricular ejection fraction may become not crucial
No full text
Improving Outcome in Patients With Tricuspid Regurgitation: Look At the Kidneys and the Liver!
No full textOctober 2023 at a glance: From prevention to diagnosis, prognosis and treatment of acute decompensation and comorbidities
Full text linkSulle fotografie danneggiate. Gestione degli organismi infestanti
Full text linkIl testo fornisce informazioni di carattere generale sulle specie animali (principalmente insetti e roditori) che con maggiore frequenza si rintracciano negli ambienti di conservazione delle fotografie e sui danni che essi possono arrecare. Una parte è dedicata alle metodologie e alle strategie di prevenzione nonché ai diversi metodi di lotta capaci di limitare le infestazioni. Sono trattate anche le varie tipologie di tecniche fotografiche e delineate le problematiche del restauro conservativo utili ad arginare gli effetti del deterioramento. Alla realizzazione dell’opera hanno contribuito diversi Autori, specialisti in vari campi disciplinari della biologia applicata e delle attività di studio interessate alla valorizzazione, conservazione, tutela e fruizione dei beni culturali
Can mild to moderate secondary mitral regurgitation be a therapeutic target for symptomatic patients with heart failure with reduced ejection fraction?
No full textDevice-based percutaneous treatments to decompress the left atrium in heart failure with preserved ejection fraction
No full textHeart failure with preserved ejection fraction (HFpEF) accounts for more than half of heart failure hospital admissions in the last years and is burdened by high mortality and poor quality of life. Providing effective management for HFpEF patients is a major unmet clinical need. Increase in left atrial pressure is the key determinant of pulmonary congestion, with consequent dyspnoea and exercise limitation. Evidence on benefits of medical treatment in HFpEF patients is limited. Thus, alternative strategies, including devices able to reduce left atrial pressure, through an interatrial communication determining a left-right shunt, were developed. This review aims to summarize evidence regarding the use of percutaneous interatrial shunting devices. These devices are safe and effective in improving hemodynamic and clinical parameters, including pulmonary capillary wedge pressure, 6-min walking distance, and New York Heart Association functional class. Data on cardiovascular mortality and re-hospitalization for heart failure are still scarce
Severe Aortic Regurgitation of Early Degenerated Mitroflow Bioprosthesis: From Echocardiographic Diagnosis to Treatment with Valve-in-Valve Transcatheter Aortic Valve Implantation
No full textValve-in-Valve transcatheter aortic valve implantation (ViV TAVI) is emerging as an effective therapeutic option for bioprosthetic valve failure. Recently, concern has been raised for early valve deterioration of Mitroflow (Sorin) aortic bioprosthesis, with the development of prevalent stenosis. We report cases of pure severe aortic regurgitation (AR) due to early and mid-term prosthesis degeneration. From June 2018 to October 2019, three patients were treated in our division for the new appearance of severe intraprosthetic regurgitation. Patient 1 (man, 85-year-old) and patient 3 (woman, 83-year-old) had a Mitroflow n. 25 and n. 21 implanted, respectively, in 2012 and 2013 for severe aortic stenosis. Patient 2, a 67-year-old woman with Marfan syndrome underwent a Mitroflow n. 25 implant in 2008 for severe AR and presented chronic type-B aortic dissection. Patient 1 was diagnosed with severe AR in the ambulatory setting, while the other patients presented acute heart failure, requiring inotrope support and high doses intravenous diuretics, and in case 3, temporary extracorporeal ultrafiltration. All patients appeared at high surgical risk and were successfully treated with ViV TAVI, through the right axillary artery in patient 2, and through the femoral artery in patients 1 and 3. Results were good at short- and mid-term follow-up. In conclusion, early and midterm bioprosthesis degeneration with the development of severe AR is a possible complication of the Mitroflow aortic valve. ViV TAVI has been confirmed as a safe and effective therapeutic option in our cases
[Sodium-glucose cotransporter 2 inhibitors and heart failure with preserved ejection fraction: the EMPEROR-Preserved and DELIVER studies]
No full text- …
